November 15, 2026 · Journal of the American Society of Nephrology : JASN · DOI: 10.1681/ASN.0000001333

Finerenone in Patients with Focal Segmental Glomerulosclerosis.

Listen to this summary

This prespecified analysis of the FIND-CKD trial asked whether finerenone, a mineralocorticoid receptor antagonist, slows kidney function decline and reduces proteinuria in people with nondiabetic CKD due to focal segmental glomerulosclerosis (FSGS). Among 215 participants with FSGS, finerenone slowed the eGFR decline by 1.3 mL/min/1.73 m²/year versus placebo, lowered urinary protein-to-creatinine ratio by 41% at 12 months, and was well tolerated with a similar rate of hyperkalemia-related events. Although the kidney composite outcome was not statistically significant (HR 0.58, 95% CI 0.30–1.15), these exploratory findings suggest finerenone may be a promising therapy for FSGS warranting confirmation in dedicated trials.

Hiddo J L Heerspink, Brendon L Neuen, Rajiv Agarwal, David Z I Cherney, Carolyn S P Lam, Katherine R Tuttle, Christoph Wanner, Pantelis Sarafidis, Glenn M Chertow, Tim Friede, Jonathan Barratt, Jürgen Floege, Alfredo Chew-Wong, Vladimir Dobronravov, Susanne B Nicholas, Hirokazu Okada, David Packham, Pablo E Pergola, Marijn M Speeckaert, Shuifu Tang, Niels Jongs, J David Smeijer, Carolina Aldworth, Mario Berger, Meike Brinker, Rania Dayoub, Marina Yael Finkelsztein, Aidan MacNamara, Patrick Schloemer, Vlado Perkovic

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play